Skip to content

Attention Control Training (ACT) in PTSD patients: a randomized controlled trial.

Attention Control Training (ACT) in PTSD patients: a randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29598
Enrollment
66
Registered
2019-07-10
Start date
2019-11-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD

Interventions

1) One group receives an ACT training: 12 sessions once a day for 5 minutes and another group receives a sham training: 12 sessions once a day for 5 minutes. 2) After the training, both groups receive

Sponsors

None.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants are admitted if PTSD has been determined in the intake with the help of the PCL-5 and LEC-5 and clinical judgment according to the DSM-5.

Exclusion criteria

Exclusion criteria: The exclusion criteria are: 1) psychotic or bipolar disorder 2) nonfluent Dutch 3) inability to use a computer keyboard 4) current psychotherapy 5) use of psychotropic medication that started within the past year. Participants will be removed from the study if their medication has to be changed during the trial. They will be admitted if they have been taking a stable dose of medication for at least 1 year.

Design outcomes

Primary

MeasureTime frame
The most important primary research variable is the decrease in PTSD symptomatology between the experimental group and the control group. We use the PCL-5 to measure this.

Secondary

MeasureTime frame
The secondary research variables are the differences in general well-being; degree of aggression and quality of life between the experimental group and the control group. We use the PHQ-4, Buss-Perry and ORS questionnaires for this.

Contacts

Public ContactBas Schrijner

GGz Praktijk

b.schrijner@ggzpraktijk.nl06-24238189

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)